Discussing issues facing the healthcare system and joys and challenges of running a healthcare technology company. Plus other things that I find interesting.
Chicago, IL
Joined March 2020
- Tweets74
- Following116
- Followers56
- Likes30
Jeremy Docken retweeted
As I have stated previously, @GoodRx is a PBM scam, another form of spread pricing.
Patients benefit from paying cash for some of the most often prescribed generic medications.
There are far better options for patients to pay cash e.g., Costco
drugchannels.net/2022/11/beh…
Jeremy Docken retweeted
I bet there are some grumpy faces up in Dublin, Ohio this evening after reading this one. Ouch.
Warren Buffett once said that the best business to be in is a royalty on the growth of others. Cardinal Health has seen declining profitability even though that's basically what a drug distributor does-- take a royalty on the growth of the pharma industry. wsj.com/articles/failing-in-…
Jeremy Docken retweeted
Insurers and PBMs are Undermining Employee Health Benefits
Employers have the power and they need to ensure that their employee drug benefits are protected from PBM/insurer profit-seeking practices
@GHLForg @ppi @PioneerBoston
healthcarebusinesstoday.com/… via @HCBizToday
Jeremy Docken retweeted
A timely reminder that #insulin #drug prices are not what they seem: "Understanding Insulin Prices"
Do politicians understand that out-of-pocket costs, not list prices, are patients’ biggest challenge?
@PioneerBoston @InsideSourcesDC #GrossToNetBubble
drugch.nl/3xb8rPW
Jeremy Docken retweeted
Drug Channels News Roundup, January 2022
In this issue:
- An update on the #GrossToNetBubble for #insulin
- OptumRx trolls us
- Patients vs. high-deductible health plans
- #340B's unstoppable growth
Plus: Fun with the CDC
Read it all here ==> drugch.nl/3KHb8NR
Jeremy Docken retweeted
Dear Lawmakers @POTUS @RonWyden @SpeakerPelosi Hundreds of us biotech investors, innovators, patient advocates, & NIH academics representing >40k US jobs, >600 drugs in trials, & >$200B invested propose solutions to affordability that preserve R&D. 1/
nopatientleftbehind.docsend.…
Jeremy Docken retweeted
The cost of drugs has long been a hot-button topic, but how might the landscape be changing for 2021? The Current State of Drug Pricing and Forecasts for the Future explores what drug makers need to know as the Biden administration tackles #drugpricing
➡️pharmexec.com/view/the-curre…
Jeremy Docken retweeted
R.I.P., #rebate rule
@HHSGov delays world w/o rebates until at least 2023, due to @pcmanet lawsuit: drugch.nl/3oBokHV
Good news for #PBMs & #GrossToNetBubble ; Bad news for patients taking deeply-discounted #drugs 😔
My still-relevant 2019 $0.02: drugch.nl/2WSR83k
Jeremy Docken retweeted
Questions: What happens to patients whose medication is no longer covered by the PBM? Do insurers who now supposedly own these PBMs care about the total cost of care due to poor outcomes?
Answers: WHO CARES & NO since rebate contracting driving this behavior is far more lucrative
Jeremy Docken retweeted
PCMA will always protect the rebate contracting gravy train, as it is the most lucrative part of the RX benefit management & AARP opposing the rebate rule is because AARP is a PBM & not a patient group as advertised
read👇
hsj.gr/medicine/reforming-re…
fiercehealthcare.com/payer/p…
Great paper showing why HHS's "world without rebates" Part D rule is good policy for directing drug discounts where they matter-to reduce patient OOP spend.
My paper published in Health Science Journal analyzing how rebate contracting for pharmaceuticals leads to higher out of pocket costs for patients, higher healthcare spending and worsening patient compliance #Pharmaceutical #healthcare #patients hsj.gr/medicine/reforming-re…
Jeremy Docken retweeted
Curious about others’ reactions to my belief that @ONC_HealthIT's info blocking rule is a really, really big deal. As in, perhaps more so than anything in the previous or next 5 years.
forbes.com/sites/sethjoseph/…
Only in 340B is margin and profit called "savings"
Big #340B profits in specialty #pharmacy, per two academic medical centers (UC Davis Health & Boston Medical Center):
- Non-340B margins = 5% to 10%
- #340B margins = 30% to 50%
Follow the dollars!
Source: @Rx_Specialty annual meeting
P.S. My $0.02: drugch.nl/2EfE6H3
Information asymmetries in healthcare have to be overcome to make our healthcare system work as voters and patients need it to work. The good news is, platforms are perfectly suited to solve information asymmetry issues by connecting stakeholders. forbes.com/sites/sethjoseph/…
Jeremy Docken retweeted
Worth reading: Pretty balanced article on #340B contract pharmacy issues from @JohnRussell99 @IBJnews drugch.nl/3iqnM4j
Jeremy Docken retweeted
My latest @WSJ opinion piece: The Federal Program That Keeps #Insulin Prices High drugch.nl/3bKJAG8
a.k.a. How the #340B #Drug Pricing Program lost its way with contract #pharmacies
Jeremy Docken retweeted
Size matters: @MedImpact 2019 #drug trend worse than big #PBMs (@CVSHealth $CVS & @ExpressScripts $CI) drugch.nl/31nQPjG
Trad'l trend higher. Specialty trend only lower due to utilization (fewer Rx), not cost
Similar to subscale @Prime_PBM (per drugch.nl/3fxt2lV)
Service providers for #340B fall into two categories: pro-pharma or pro-covered entity. If you are pro-pharma, you make covered entities the enemy in sell. If you are pro-covered entities, you make manufacturers the enemy in order to close business. @KalderosInc is different.
Jeremy Docken retweeted
FYI: @ahahospitals expresses "profound concern" over manufacturer actions re: #340B #contract #pharmacies drugch.nl/2Ypt2Oz
Letter to @SecAzar @HHSGov: drugch.nl/32fvGaF
Note: AHA doesn't (and can't) allege actions are "illegal" b/c it's all subregulatory!